FDA grants Breakthrough Device Designation for Fractyl's Revita in weight maintenance after GLP-1 discontinuation

FRACTYL HEALTH, INC.

Revita targets duodenal lining; aims to maintain weight loss after stopping GLP-1 drugs.
Breakthrough Device Designation enables priority FDA review and potential CMS reimbursement support.
REMAIN-1 pivotal study underway; data readouts expected starting Q4 2024, mid-point analysis Q2 2025.
Designation based on prior pooled weight data from T2D studies showing durable weight maintenance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.